These classes of drugs are of growing importance as a therapeutical approach in inflammatory and autoimmune diseases such as RA by regulating IL-17A, IL-22, and IFN-γ levels, but with a few significant cardiovascular side effects [17, 18]. This evidence concerns the gene IL17A and rheumatoid arthritis.